In recent years, we have seen rapid growth in the development of adeno-associated virus (AAV)-mediated gene therapy products that target fatal and highly debilitating diseases. Growth is evident in ...
Good Manufacturing Practice (GMP) compliance in adeno-associated virus (AAV)-based cell and gene therapy development can pose significant challenge, including proving capsid ratios to regulators and ...
The successes seen in a number of clinical studies on viral vector-based gene therapies (AAV, retroviral, and lentiviral vectors) are well documented, with an ever-broadening pipeline of products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results